Neurocrine Reports Mixed Q4 with Strong EPS Growth

Neurocrine Biosciences reports Q4 results with strong adjusted EPS beating estimates, despite slight revenue miss. Investors should take note of its robust product performance and strategic outlook.

Date: 07-02-2025

AI Rating: 7

Earnings Per Share (EPS)
Neurocrine Biosciences reported an adjusted EPS of $1.69, significantly exceeding the estimate of $1.58. This marks a year-over-year increase of 9.7% from $1.54.

Revenue Growth
The company reported revenue of $627.7 million for Q4, which is slightly below the expectation of $629 million. However, this reflects a strong 22% growth compared to $515.2 million in Q4 2023.

Net Income
Neurocrine posted a GAAP net income of $103.1 million, with a diluted EPS of $1.00, which declined from $1.44 in the prior year, but non-GAAP net income increased to $173.4 million due to strong sales.

Profit Margins
The report highlights improved margins reflected in its increasing net product sales, which reached $621.2 million, up 23% year-over-year, indicating strong profit generation capabilities.

Free Cash Flow (FCF) and Return on Equity (ROE)
No specific information was provided on FCF or ROE in the text.

Neurocrine's continued focus on innovation and addressing competitive pressures through strategic initiatives is evident. The projected sales of Ingrezza are expected to reach between $2.5 billion to $2.6 billion in 2025, promising future growth driven by strong pipeline and market presence. Despite a slight revenue miss, the positive EPS growth and overall strong product sales performance highlight the company's resilience and strategic direction.

Stocks: NBIX TEVA